---
figid: PMC9399644__fcell-10-942828-g005
figtitle: Advances in the study of HSP70 inhibitors to enhance the sensitivity of
  tumor cells to radiotherapy
organisms:
- NA
pmcid: PMC9399644
filename: fcell-10-942828-g005.jpg
figlink: /pmc/articles/PMC9399644/figure/F5/
number: F5
caption: Anti-tumor Angiogenesis by HSP70 Inhibitors. HSP70 inhibitors can increase
  the radiosensitivity of tumor cells through anti-tumor angiogenesis. For example,
  in pancreatic cancer, TPL inhibits tumor angiogenesis by inhibiting Tie2 and VEGFR-2;
  in acute myeloid leukemia and breast cancer, quercetin targets the VEGFR-2-mediated
  angiogenic pathway and inhibits the expression of the downstream regulator AKT;
  in breast cancer, EGCG is anti-tumor angiogenic by inhibiting the expression of
  VEGF and suppressing the phosphorylation levels of EGFR and ERK1/2.
papertitle: Advances in the study of HSP70 inhibitors to enhance the sensitivity of
  tumor cells to radiotherapy.
reftext: Sihan Du, et al. Front Cell Dev Biol. 2022;10:942828.
year: '2022'
doi: 10.3389/fcell.2022.942828
journal_title: Frontiers in Cell and Developmental Biology
journal_nlm_ta: Front Cell Dev Biol
publisher_name: Frontiers Media S.A.
keywords: HSP70 | HSP70 inhibitor | radiotherapy | sensitivity | tumour
automl_pathway: 0.9125272
figid_alias: PMC9399644__F5
figtype: Figure
organisms_ner:
- Drosophila melanogaster
- Homo sapiens
redirect_from: /figures/PMC9399644__F5
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC9399644__fcell-10-942828-g005.html
  '@type': Dataset
  description: Anti-tumor Angiogenesis by HSP70 Inhibitors. HSP70 inhibitors can increase
    the radiosensitivity of tumor cells through anti-tumor angiogenesis. For example,
    in pancreatic cancer, TPL inhibits tumor angiogenesis by inhibiting Tie2 and VEGFR-2;
    in acute myeloid leukemia and breast cancer, quercetin targets the VEGFR-2-mediated
    angiogenic pathway and inhibits the expression of the downstream regulator AKT;
    in breast cancer, EGCG is anti-tumor angiogenic by inhibiting the expression of
    VEGF and suppressing the phosphorylation levels of EGFR and ERK1/2.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - sm
  - ec
  - Tpl
  - Tpl94D
  - Pi3K21B
  - Pi3K59F
  - Pi3K68D
  - Pi3K92E
  - Akt
  - Hsc70-3
  - Hsc70-1
  - Hsc70-4
  - Hsp70Ab
  - Hsp70Ba
  - Hsp70Aa
  - Hsp70Bb
  - Hsp70Bc
  - Hsp70Bbb
  - Fak
  - p38b
  - p38a
  - p38c
  - MKP-4
  - rl
  - lic
  - Nurf-38
  - Ebp
  - AIMP2
  - Hrb87F
  - Nos
  - nos
  - Src42A
  - Csk
  - Src64B
  - btl
  - htl
  - Smox
  - Egfr
  - sl
  - KDR
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - AKT1
  - AKT2
  - AKT3
  - TEK
  - HSPA1A
  - HSPA4
  - PTK2
  - MAPK1
  - MAPK3
  - MAPK11
  - MAPK12
  - MAPK13
  - MAPK14
  - MAPK8
  - MAPK9
  - MAPK10
  - CRK
  - GRAP2
  - AHSA1
  - POLDIP2
  - NOS1
  - NOS2
  - NOS3
  - SRC
  - FGR
  - FYN
  - YES1
  - FGFR1
  - FGFR2
  - FGFR3
  - FGFR4
  - FGFRL1
  - IGF1R
  - SMAD2
  - SMAD3
  - EGFR
  - PLCG1
  - PLCG2
---
